Skip to content
MedsAcross

Molecule

Tetracycline

Also known as tetracycline hydrochloride
Presentations
4
Brands
0
Manufacturers
0
Available from stock
0

Tetracycline is a tetracycline-class antimicrobial indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below. It is available as capsules and tablets for oral use. MedsAcross supplies Tetracycline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Tetracycline-class Antimicrobial
ATC classification
A01AB13 Tetracycline · Medications used in dentistry and periodontics, subgroup A01ABD06AA04 Tetracycline · Antibiotics and antivirals for the skin, subgroup D06A, subgroup D06AAJ01AA07 Tetracycline · TetracyclineS01AA09 Tetracycline · Eye medicines, subgroup S01A, subgroup S01AAS02AA08 Tetracycline · Anti-infective agentS03AA02 Tetracycline · Anti-infective agent
US FDA first approval
19 November 1953
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Capsule, Tablet
Identifiers
UNII F8VB5M810TRxCUI 10395CAS 60-54-8DrugBank DB00759Q193045

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae.

Source: US FDA prescribing information

Dosing overview

Adults: Usual daily dose, 1 gram as 500 mg twice a day or 250 mg four times a day. Higher doses such as 500 mg four times a day may be required for severe infections or for those infections which do not respond to the smaller doses. For pediatric patients above eight years of age: Usual daily dose, 10 mg/lb to 20 mg/lb (25mg/kg to 50 mg/kg) body weight divided in four equal doses. Administration of adequate amounts of fluid with the capsule formulation of tetracycline is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. Absorption of tetracycline is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc or sodium bicarbonate. Food and some dairy products also interfere with absorption. When used in streptococcal infections, therapy should be continued for 10 days.

Source: US FDA prescribing information

Contraindications

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

Source: US FDA prescribing information

Warnings and precautions

Tooth Development The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Tetracycline drugs should not be used in this age group, except for anthrax, unless other drugs are not likely to be effective or are contraindicated. Clostridium difficile Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including tetracyclines, and may range in severity from mild diarrhea to fatal colitis.

Source: US FDA prescribing information

Side effects

Gastrointestinal: anorexia, nausea, epigastric distress, vomiting, diarrhea, glossitis, black hairy tongue, dysphagia, enterocolitis, and inflammatory lesions (with Candida overgrowth) in the anogenital region. Esophagitis and esophageal ulceration have been reported in patients receiving particularly the capsule and also the tablet forms of tetracyclines. Most of the patients were reported to have taken medication immediately before going to bed. Teeth: permanent discoloration of teeth may be caused during tooth development. Enamel hypoplasia has been reported. Skin: fixed drug eruption, maculopapular and erythematous rashes. Exfoliative dermatitis has been reported. Onycholysis and discoloration of the nails have been reported. Photosensitivity is discussed in WARNINGS. Renal Toxicity: an increase in BUN has been reported and is dose related.

Source: US FDA prescribing information

Interactions

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline in conjunction with penicillin or other bactericidal antibacterials. Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate. Concurrent use of tetracycline may render oral contraceptives less effective.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

4 presentations of Tetracycline, sorted by availability.

MedicineManufacturerRegisterAvailability
Tetracycline 500 mg capsuleOralGeneric name—US FDAAvailable on request
Tetracycline 250 mg capsuleOralGeneric name—US FDAAvailable on request
Tetracycline 250 mg tabletOralGeneric name—US FDAAvailable on request
Tetracycline 500 mg tabletOralGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 19 November 1953Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Tetracycline in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Tetracycline available for export from India?

Yes, on request. MedsAcross lists 4 presentations of Tetracycline and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Tetracycline approved by the US FDA?

Yes. The US FDA first approved Tetracycline on 19 November 1953, according to Drugs@FDA.

Does Tetracycline need cold chain shipping?

No listed presentation of Tetracycline is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Tetracycline in?

Tetracycline is classified under ATC code A01AB13 (Tetracycline).

References

  1. tetracycline hydrochloride prescribing information (Avet Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 18 March 2025

Request Tetracycline for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.